OUR TECHNOLOGY IS UNMATCHED. SO IS OUR LEADERSHIP.

Stephen J. Fanning was appointed President and Chief Executive Officer of Solta Medical, Inc. (formerly Thermage, Inc.), a global leader in the medical aesthetics market, on January 15, 2005. He was elected Chairman of the Board of Directors effective July 31, 2006. Under his leadership, the Company went public in November 2006, raising $42 million. Also, in January 2009, he led the successful integration of the acquisition of Reliant Technologies, Inc., which combined the industry's two leading brands, Thermage® and Fraxel®, under a new corporate name of Solta Medical Inc., forming a global leader in aesthetic energy devices. In 2010, he led two additional successful integrations with the acquisition of Aesthera Corporation and CLRS Inc. bringing together the Isolaz® and CLARO® brands of products for the treatment of acne with Solta´s leading brands for skin tightening and skin resurfacing. Recently, under Mr. Fanning´s direction, Solta has announced it has reached an agreement for the acquisition of LIPOSONIX, a leading solution in the non-invasive destruction of fat, which will significantly broaden Solta's current market opportunity. Mr. Fanning has an extensive background in the healthcare, consumer pharmaceuticals and consumer package goods industries.

Mr. Fanning joined Thermage, Inc. from Ocular Sciences, Inc., a $350 million global public company, which developed, manufactured and marketed disposable contact lenses. Mr. Fanning had been President and Chief Executive Officer of the Company and a member of the Board of Directors since August 13, 2001. Under his leadership, Ocular Sciences implemented a next–generation manufacturing process, significantly driving down the cost of goods sold, achieved significant increases in global market share and attained more than $300 million in annual sales. In January 2005, Ocular Sciences was successfully acquired by CooperVision for $1.3 billion.

Mr. Fanning joined Ocular Sciences from Johnson & Johnson (J&J), one of the world´s largest manufacturers of healthcare products, where he served in various senior executive positions of escalating responsibility for 25 years. His most recent position was President, Worldwide, of J&J´s McNeil Specialty Products division. Prior to that, he served as President of Johnson & Johnson Medical, a medical device company. Mr. Fanning has also served as Managing Director of J&J Austria/Switzerland, and Vice President, Sales, of J&J´s McNeil Consumer Products Division.

Mr. Fanning holds a Bachelor of Science degree from Philadelphia University.

Bill Brodie joined Thermage in February of 2006 as Director of Sales, Eastern US. Mr. Brodie was promoted to Vice President of Global Sales in January of 2009. He brings more than 17 years of sales management experience and business development in both the medical and dental markets. Most recently, he served as Vice President of Sales and Field Operations with Benco Dental Company, a leader in dental office equipment sales, office design and supply management. His responsibilities for this $300 million, privately-held company included leading a sales force of over 600 field personnel, as well as inside sales, international sales, and practice development consulting. From 1998 to 2002 he held various sales management positions with Benco. Prior to 1998 Mr. Brodie was the founder, president and owner of Quality Central Dental a dental sales company based in Orlando, FL until the 1998 merger with Benco. He holds a Master of Science in Management from Georgia Institute of Technology, and a Bachelor of Science from Rollins College.

Dan Ferrari joined Thermage in November 2004 and brings more than 20 years of financial management experience with both public and private companies including over 11 years in the medical device industry. From 2001 to 2004, Mr. Ferrari served as Vice President, Corporate Controller of Critical Path, Inc., a $70 million revenue publicly held enterprise software and hosted messaging company, where he rebuilt the financial organization, established strong financial controls, and managed restructuring of the company. From 1999 to 2001, Mr. Ferrari was a financial consultant for a number of private companies, advising executive management regarding business model optimization, mergers and acquisitions, funding strategy, the IPO process and other financial matters. Prior to consulting, Mr. Ferrari served as Vice President, Finance of ReSound, Inc. a publicly held hearing device company, and was with the company from 1994 through 1999. During his tenure at ReSound, Mr. Ferrari was a major contributor on several acquisitions, establishment of an offshore manufacturing facility, and a number of securities offerings as revenues grew from $35 million to over $125 million prior to sale of the company to GN Great Nordic. Mr. Ferrari holds a BS in Commerce and MBA from Santa Clara University.

Kris Foss joined Solta Medical in February 2010 as Vice President of Regulatory, Clinical and Quality. Ms. Foss has more than 20 years of experience in regulatory and clinical management in the medical device industry. Most recently, she served as Vice President, Global Regulatory and Clinical with UltraShape where she was responsible for aesthetic device marketing approvals, clinical development programs and regulatory compliance. Prior to UltraShape, Ms. Foss was Vice President, Clinical and Regulatory Affairs with Mentor where she was responsible for securing PMA approval for the company’s silicone gel breast implants. Prior to Mentor, Ms. Foss held similar executive regulatory and clinical management positions with both public and private companies, including many having experienced successful IPO transactions. Ms. Foss holds a B.A. from Northwestern University and is a certified regulatory affairs professional (RAC).

Jack Glenn joined Thermage in January 2008 as Chief Financial Officer, bringing with him almost 25 years of financial leadership experience with both private and publicly traded companies. He joins the Company from Cholestech, Inc., a publicly traded company providing diagnostic tools for the monitoring and assessment of heart disease, where he held the role of Chief Financial Officer and Vice President of Finance for three years before assisting in its strategic acquisition by Inverness Medical Innovations. Prior to Cholestech, Mr. Glenn held the role of Chief Financial Officer and Vice President of Finance for Invivo Corporation for 14 years. Invivo Corporation, a publicly traded medical device manufacturer, was sold to Intermagnetics in January of 2004. During Mr. Glenn's tenure at Invivo Corporation, he played a key role in the identification, negotiation and structuring of four successful acquisitions, two secondary public equity offerings and two divestitures of non-strategic businesses. Mr. Glenn holds a BS in business administration from the University of Nevada and an MBA from Santa Clara University.

Doug Heigel joined Thermage in May of 2002 as Senior Director of Operations and in July of 2003 he was promoted to the position of Vice President of Operations. He has more than 20 years of management experience involving engineering, manufacturing, supply chain management and product service related to scientific instrumentation, capital equipment and related consumables. From 1995 until 2002, Mr. Heigel was Vice President of Manufacturing for Argonaut Technologies, a manufacturer of automated synthesis equipment and chemistry consumables utilized in pharmaceutical and biotech drug discovery research. Mr. Heigel developed Argonaut's instrument manufacturing capability and introduced several successful instrument product lines that propelled Argonaut through a successful IPO in 2000. From 1988 to 1995 Mr. Heigel held Engineering and Operations Management positions at Microsensor Technology, a manufacturer of innovative, portable gas analyzers that was acquired by Agilent Technologies. Mr. Heigel earned his BS in Mechanical Engineering from Oregon State University.

Jeff Nardoci joined Solta Medical in September 2009 as Vice President of Global Marketing. Jeff brings more than 19 years of experience in marketing and strategic consumer development in both the medical and consumer goods markets. Most recently, Jeff served as Vice President of Commercial Operations, U.S. Vision Care with Bausch & Lomb, where he was responsible for a $530 million portfolio of lens, lens care and OTC pharmaceuticals. Mr. Nardoci spent 11 years at Bausch & Lomb in increasingly responsible positions. Prior to Bausch & Lomb, he was an executive consultant at Meridian Euro RSCG, a sales and marketing consulting group. His experience also includes seven years at Nabisco in the specialty foods marketing organization. Mr. Nardoci has a B.A. in Economics from Fairleigh Dickinson University.

Tom Yorkey joined Solta in October of 2010 as the Senior Director of Technology Development and was promoted to the Vice President of Research and Development in January 2011. Mr. Yorkey has more than 20 years of medical device experience. Most recently, he served as the Vice President of Research and Development at Spiracur, wound care device company. Prior to Spiracur, Mr. Yorkey was the Vice President of Research and Development at NeoGuide Systems, a robotic endoscope company that was sold to Intuitive Surgical. Prior to NeoGuide, Mr. Yorkey had similar executive roles in Research and Development including Nellcor Puritan Bennett, a division of Tyco Healthcare. He holds a Ph.D. in Electrical Engineering from the University of Wisconsin, Madison and a Bachelor of Science degree in Electrical Engineering from the State University of New York at Buffalo.